Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Latest From Andrew McConaghie

Pfizer Chief Calls Patent Pool ‘Nonsense’, Fears Tussle Over Vaccine

Pharma will oppose a patent pool, but the world still needs a way to guarantee fair access to COVID-19 vaccines.

Commercial Companies

Latecomer Merck Enters Coronavirus Vaccine Field With Themis Acquisition

While Moderna and others frontrunners aim for a 2020 emergency use approval, Merck believes a more deliberate approach will pay off in the long term.

Coronavirus COVID-19 Companies

Vaccine Manufacturing Hub Will Help UK Meet Coronavirus Challenge

Vaccine manufacturing capacity has been lost in the UK in recent decades. Now a new Vaccines Manufacturing Innovation Centre will re-seed that capacity and expertise - and the pandemic is accelerating its arrival.

Companies Clinical Trials

Vaccine Manufacturing Hub Will Help UK Meet Coronavirus Challenge

Vaccines manufacturing capacity has been lost in the UK over recent decades. Now a new Vaccines Manufacturing Innovation Centre will re-seed that capacity and expertise - and the pandemic is accelerating its arrival.  

Companies Coronavirus COVID-19

Trump Is Taking Hydroxychloroquine – But Global Prevention Trial Is Deadly Serious

Experts fear Trump’s unregulated use of the malaria drug is dangerous, and muddies the waters around research which could still find chloroquine useful in preventing SARS-CoV-2 infection.

Coronavirus COVID-19 Research & Development

Moderna’s Early Data On COVID-19 Vaccine Prompts Dosing Revisions For Phase II

Move to lower doses could ease manufacturing scale-up burden a bit; first eight volunteers produced antibodies which match or surpass those seen in patients who have recovered from COVID-19 – but big test awaits in Phase III.

Coronavirus COVID-19 Vaccines
See All
UsernamePublicRestriction

Register